Could a shot help people with multiple food allergies eat peanuts safely?
NCT ID NCT03881696
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether omalizumab (Xolair), an allergy drug, helps people with peanut and at least two other food allergies eat those foods without severe reactions. Over 470 participants aged 1 to 55 received omalizumab or a placebo, and some also got oral immunotherapy. The goal was to see if they could tolerate a dose of peanut protein without symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
omalizumab (Xolair) and multi-allergen oral immunotherapy
What this could lead to
If successful, this could provide a new treatment option to help people with multiple food allergies tolerate small amounts of allergenic foods without severe reactions.
What could go wrong
This is a completed phase 3 trial, but results may not apply to all food allergies or ages. Omalizumab is not a cure and requires ongoing injections; risks include allergic reactions and side effects from the drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEANUT ALLERGY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arkansas Children's Hospital Research Institute: Department of Pediatrics, Allergy & Immunology
Little Rock, Arkansas, 72202, United States
-
Children's Hospital of Philadelphia: Division of Allergy and Immunology
Philadelphia, Pennsylvania, 19104, United States
-
Emory University School of Medicine: Children's Healthcare of Atlanta Pediatrics
Atlanta, Georgia, 30307, United States
-
Icahn School of Medicine at Mount Sinai: Department of Pediatrics Allergy & Immunology
New York, New York, 10029, United States
-
Johns Hopkins Children's Center: Department of Allergy & Immunology
Baltimore, Maryland, 21287, United States
-
Massachusetts General Hospital, Department of Medicine: Allergy & Clinical Immunology Unit
Boston, Massachusetts, 02114, United States
-
National Jewish Health: Division of Pediatric Allergy and Clinical Immunology
Denver, Colorado, 80206, United States
-
North Carolina Children's Hospital: Department of Pediatrics, Division of Allergy, Immunology and Rheumatology
Chapel Hill, North Carolina, 27599-7000, United States
-
Stanford School of Medicine: Sean N. Parker Center for Allergy & Asthma Research
Stanford, California, 94305, United States
-
University of Texas Southwestern Medical Center: Division of Allergy and Immunology
Dallas, Texas, 75390, United States